Chandler, Arizona (PRWEB) January 10, 2013
Dr. Smith will oversee all of HealthTell’s diagnostic chip manufacturing and technical infrastructure development.
“Dr. Smith’s diverse background in biotechnology management and proven execution capabilities give him a unique combination of skills necessary to lead our operations”, said Bill Colston, CEO of HealthTell. “He provides a critical asset in helping us commercialize and provide the enormous economies of scale necessary to meet our business strategy.”
Prior to his new position, Dr. Smith served in senior leadership positions across multiple biotechnology companies, including Affymetrix, 454 Life Sciences, and Codon Devices. A common theme across these companies was Dr. Smith’s ability to transition complex technology from early feasibility to mass production within very short time frames.
Dr. Smith received his BS degree in chemistry from North Central College and his Ph.D. in chemistry from University of Arizona.
HealthTell, Inc. is an early stage life sciences company focused on providing a service for early screening of cancer and other chronic diseases. HealthTell has developed a unique technology for measuring the “temperature” of an individual’s immune system from a single drop of blood. Similar to how a fever can be used to register the presence of an infection, this assay measures the immune response created by the amplification of billions of antibody molecules in response to specific diseases. HealthTell’s test provides the most specific, early possible detection of disease.
More information about HealthTell is available at http://www.healthtell.com.